Metabolic remodeling in glioblastoma: a longitudinal multi-omics study.
Glioblastoma
Liquid biopsy
Mass spectrometry
Metabolomic
Proteomic
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
07
07
2024
accepted:
06
09
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
epublish
Résumé
Monitoring tumor evolution and predicting survival using non-invasive liquid biopsy is an unmet need for glioblastoma patients. The era of proteomics and metabolomics blood analyzes, may help in this context. A case-control study was conducted. Patients were included in the GLIOPLAK trial (ClinicalTrials.gov Identifier: NCT02617745), a prospective bicentric study conducted between November 2015 and December 2022. Patients underwent biopsy alone and received radiotherapy and temozolomide. Blood samples were collected at three different time points: before and after concomitant radiochemotherapy, and at the time of tumor progression. Plasma samples from patients and controls were analyzed using metabolomics and proteomics, generating 371 omics features. Descriptive, differential, and predictive analyses were performed to assess the relationship between plasma omics feature levels and patient outcome. Diagnostic performance and longitudinal variations were also analyzed. The study included 67 subjects (34 patients and 33 controls). A significant differential expression of metabolites and proteins between patients and controls was observed. Predictive models using omics features showed high accuracy in distinguishing patients from controls. Longitudinal analysis revealed temporal variations in a few omics features including CD22, CXCL13, EGF, IL6, GZMH, KLK4, and TNFRSP6B. Survival analysis identified 77 omics features significantly associated with OS, with ERBB2 and ITGAV consistently linked to OS at all timepoints. Pathway analysis revealed dynamic oncogenic pathways involved in glioblastoma progression. This study provides insights into the potential of plasma omics features as biomarkers for glioblastoma diagnosis, progression and overall survival. Clinical implication should now be explored in dedicated prospective trials.
Identifiants
pubmed: 39394177
doi: 10.1186/s40478-024-01861-5
pii: 10.1186/s40478-024-01861-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Banques de données
ClinicalTrials.gov
['NCT02617745']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
162Informations de copyright
© 2024. The Author(s).
Références
Ostrom QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY et al (2023) National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 25:799–807
doi: 10.1093/neuonc/noac198
pubmed: 35994777
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma | NEJM [Internet]. [cited 2023 Sep 28]. Available from: https://doi.org/10.1056/NEJMoa043330
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial - PubMed [Internet]. [cited 2023 Oct 31]. Available from: https://pubmed.ncbi.nlm.nih.gov/29260225/
van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC et al (2023) Primary brain tumours in adults. Lancet 402:1564–1579
doi: 10.1016/S0140-6736(23)01054-1
pubmed: 37738997
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma in: Neurosurgical Focus Volume 53 Issue 6 (2022) Journals [Internet]. [cited 2023 Oct 31]. Available from: https://thejns.org/focus/view/journals/neurosurg-focus/53/6/article-pE14.xml
Fontanilles M, Marguet F, Beaussire L, Magne N, Pépin L-F, Alexandru C et al (2020) Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. Acta Neuropathol Commun 8:179
doi: 10.1186/s40478-020-01057-7
pubmed: 33148330
pmcid: 7641818
Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D et al (2018) TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: a pilot prospective study. Clin Cancer Res 24:5282–5291
doi: 10.1158/1078-0432.CCR-17-3717
pubmed: 29941484
Detection of circulating tumor DNA in early- and late-stage human malignancies - PubMed [Internet]. [cited 2023 Oct 31]. Available from: https://pubmed.ncbi.nlm.nih.gov/24553385/
Ahmed M, Semreen AM, El-Huneidi W, Bustanji Y, Abu-Gharbieh E, Alqudah MAY, et al. (2023) Preclinical and clinical applications of metabolomics and proteomics in glioblastoma research. Int J Mol Sci. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820403/
Dastmalchi F, Deleyrolle LP, Karachi A, Mitchell DA, Rahman M (2021) Metabolomics monitoring of treatment response to brain tumor immunotherapy. Front Oncol 11:691246
doi: 10.3389/fonc.2021.691246
pubmed: 34150663
pmcid: 8209463
He W, Edney MK, Paine SML, Griffiths RL, Scurr DJ, Rahman R et al (2023) Untargeted metabolomic characterization of glioblastoma intra-tumor heterogeneity using OrbiSIMS. Anal Chem 95:5994–6001
doi: 10.1021/acs.analchem.2c05807
pubmed: 36995369
pmcid: 10100400
N T, S K, J L, K Z, D M, V I, et al. The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers. Acta neuropathologica [Internet]. Acta Neuropathol; 2022 [cited 2023 Feb 22];144. Available from: https://pubmed.ncbi.nlm.nih.gov/36178522/
Lb W, A K, Ma G, Je K, S C, Y L, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer cell [Internet]. Cancer Cell; 2021 [cited 2022 Nov 17];39. Available from: https://pubmed.ncbi.nlm.nih.gov/33577785/
Gilard V, Ferey J, Marguet F, Fontanilles M, Ducatez F, Pilon C et al (2021) Integrative metabolomics reveals deep tissue and systemic metabolic remodeling in glioblastoma. Cancers (Basel) 13:5157
doi: 10.3390/cancers13205157
pubmed: 34680306
Qazi MA, Salim SK, Brown KR, Mikolajewicz N, Savage N, Han H et al (2022) Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Rep 40:111420
doi: 10.1016/j.celrep.2022.111420
pubmed: 36170831
Ramsay SL, Stoeggl WM, Weinberger KM, Graber A, Guggenbichler W (2012) Apparatus and method for analyzing a metabolite profile. Google Patents
Ghorbani A, Avery LM, Sohaei D, Soosaipillai A, Richer M, Horbinski C, McCortney K, Xu W, Diamandis EP, Prassas I (2023) Discovery of novel glioma serum biomarkers by proximity extension assay. Clin Proteom 20(1):12. https://doi.org/10.1186/s12014-023-09400-5 .
Ghorbani A, Chatanaka MK, Avery LM, Wang M, Brown J, Cohen R, Gorham T, Misaghian S, Padmanabhan N, Romero D, Stengelin M, Mathew A, Sigal G, Wohlstadter J, Horbinski C, McCortney K, Xu W, Zadeh G, Mansouri A, Yousef GM, Diamandis EP, Prassas I (2024) Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers. Clin Proteomi 21(1):41. https://doi.org/10.1186/s12014-024-09492-7 .
Qin Y-Y, Huang X-R, Zhang J, Wu W, Chen J, Wan S et al (2022) Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction. Mol Ther 30:881–897
doi: 10.1016/j.ymthe.2021.10.005
pubmed: 34628054
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol 136(5):805–10. https://doi.org/10.1007/s00401-018-1913-0 .
Westphal M, Maire CL, Lamszus K (2017) EGFR as a target for glioblastoma treatment: an unfulfilled promise. CNS Drugs 31:723–735
doi: 10.1007/s40263-017-0456-6
pubmed: 28791656
pmcid: 5573763
Cardona AF, Jaramillo-Velásquez D, Ruiz-Patiño A, Polo C, Jiménez E, Hakim F et al (2021) Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J Neurooncol 154:353–364
doi: 10.1007/s11060-021-03834-3
pubmed: 34498213
Drucker KL, Gianinni C, Decker PA, Diamandis EP, Scarisbrick IA (2015) Prognostic significance of multiple kallikreins in high-grade astrocytoma. BMC Cancer 15:565
doi: 10.1186/s12885-015-1566-5
pubmed: 26231762
pmcid: 4521496
Wildburger NC, Wood PL, Gumin J, Lichti CF, Emmett MR, Lang FF et al (2015) ESI-MS/MS and MALDI-IMS localization reveal alterations in phosphatidic acid, diacylglycerol, and DHA in glioma stem cell xenografts. J Proteome Res 14:2511–2519
doi: 10.1021/acs.jproteome.5b00076
pubmed: 25880480
pmcid: 4912016
Sonkar K, Ayyappan V, Tressler CM, Adelaja O, Cai R, Cheng M et al (2019) Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed 32:e4112
doi: 10.1002/nbm.4112
pubmed: 31184789
pmcid: 6803034
Wan Z, Zuo X, Wang S, Zhou L, Wen X, Yao Y, Song J, Gu J, Wang Z, Liu R, Luo C (2023) Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma. Cancer Med 12(16):17445–67. https://doi.org/10.1002/cam4.6316 .